Great post Davy, very informative but for me it begs the...

Great post Davy, very informative but for me it begs the question that clinical trials seem to be very conservative regarding dosage quantities in their initial trial programmes which is understandable. But given the results thus far with cf-33 why are they not increasing the dosage levels for those with terminal stage 4 cancers that have nothing to lose by increasing the dosages? This would confirm outright that IMU has either solved the riddle or is well on the way to solving this cancer puzzle or it doesn't work. Is it because of regulation by governing bodies? Or are the oncologists wanting to take baby steps and play it safe so that they have everything checked and double checked before increasing dosage levels. Appreciate your feedback from one that is not a medico and has very limited knowledge in this field. Cheers